BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 26, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NVC-422: Phase IIa data

In a double-blind, dose-ranging, Dominican Phase IIa trial in 129 patients ages 2-12 with impetigo due to Staphylococci infections, thrice-daily low-, mid- and high-dose topical NVC-422 for 7 days produced respective clinical response rates of 85%, 87% and 92%...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >